Clin2
NCT07444814Possibly a fitRecruiting

HWK-007 for advanced solid tumors

Endometrial CancerOvarian CancerOvarian Cancer MetastaticOvarian Cancer Metastatic RecurrentNon-squamous EGFR Wt NSCLCPlatinum Resistant Ovarian CancerPROC

Part of Cancer, Hormones & metabolism, Lungs & breathing, Women’s health & pregnancy clinical trials.

This trial tests a new drug called HWK-007, which is designed to target and attack cancer cells while sparing healthy ones. It is for people with specific advanced solid tumors (lung, endometrial, or ovarian cancer) that have not responded well to standard treatments.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1
Enrollment
226 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You have one of these cancers: non-squamous EGFR-wildtype non-small cell lung cancer, endometrial cancer, or platinum-resistant ovarian cancer.
  • Your cancer is advanced and cannot be removed by surgery, or has spread to other parts of the body.
  • You have no known or uncontrolled brain metastases.
  • You have no history of cornea transplant or certain eye surface problems.
  • You have not had pneumonitis or interstitial lung disease.
  • You are not pregnant, breastfeeding, or planning to become pregnant during the study.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07470853Recruiting· Phase 1
Study of HWK-016 for advanced ovarian or endometrial cancer

This trial tests a new drug called HWK-016, which is designed to target and deliver medicine directly to cancer cells that have a specific marker (MUC16). It is for people with advanced ovarian or endometrial cancer to see if it can shrink tumors or slow their growth.

Little Rock, Arkansas
NCT06014190Recruiting· Phase 2
HS-20089 for ovarian and endometrial cancer

This trial tests a new medication (HS-20089) for people with ovarian or endometrial cancer that has come back or spread. It aims to see if the drug can shrink tumors or slow cancer growth.

Hefei, Anfei
NCT06882135Recruiting· Phase 1
Testing an experimental drug for advanced solid tumors

This trial studies a new drug called HW071021 for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug can help shrink or control the cancer.

Guangzhou, Guangdong
NCT06314373Recruiting· Phase 1/Phase 2
Study of a new drug for advanced solid tumors

This trial tests a new drug called HSK39775 for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug is safe and effective for people who have few other options.

Shanghai, Shanghai Municipality
NCT06304571Recruiting· Phase 1
Study of HC006 for advanced solid tumors

This study tests a new drug called HC006 for advanced solid tumors that no longer respond to standard treatments. It aims to find a safe dose and see if it helps shrink tumors.

Shanghai, Shanghai Municipality
NCT07719920Not yet recruiting· Phase 1
Study of HW221043 for advanced solid tumors

This trial is testing a new oral drug called HW221043 for people with advanced solid tumors that have not responded to other treatments. The goal is to see if it is safe and how well it works.

Shanghai, Shanghai Municipality

Hear when a new Endometrial Cancer trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.